CN115697997B - 具有gpr52促效活性的经取代的3-苯氧基氮杂环丁烷-1-基-吡嗪 - Google Patents

具有gpr52促效活性的经取代的3-苯氧基氮杂环丁烷-1-基-吡嗪 Download PDF

Info

Publication number
CN115697997B
CN115697997B CN202180025462.7A CN202180025462A CN115697997B CN 115697997 B CN115697997 B CN 115697997B CN 202180025462 A CN202180025462 A CN 202180025462A CN 115697997 B CN115697997 B CN 115697997B
Authority
CN
China
Prior art keywords
mol
mixture
group
schizophrenia
room temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180025462.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN115697997A (zh
Inventor
K·杰拉克
B·贝尔塔尼
M·费拉拉
G·福萨蒂
S·霍布森
U·F·莱塞尔
F·伦杰
G·森普尔
U·穆勒-维埃拉
J·维皮奇
Y·熊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Arena Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Arena Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Publication of CN115697997A publication Critical patent/CN115697997A/zh
Application granted granted Critical
Publication of CN115697997B publication Critical patent/CN115697997B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180025462.7A 2020-03-30 2021-03-29 具有gpr52促效活性的经取代的3-苯氧基氮杂环丁烷-1-基-吡嗪 Active CN115697997B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063001640P 2020-03-30 2020-03-30
US63/001,640 2020-03-30
PCT/EP2021/058099 WO2021198149A1 (en) 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Publications (2)

Publication Number Publication Date
CN115697997A CN115697997A (zh) 2023-02-03
CN115697997B true CN115697997B (zh) 2024-07-30

Family

ID=75362607

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180025462.7A Active CN115697997B (zh) 2020-03-30 2021-03-29 具有gpr52促效活性的经取代的3-苯氧基氮杂环丁烷-1-基-吡嗪

Country Status (20)

Country Link
US (1) US11780827B2 (https=)
EP (1) EP4126850B1 (https=)
JP (1) JP7617134B2 (https=)
KR (1) KR20220161454A (https=)
CN (1) CN115697997B (https=)
AR (1) AR121675A1 (https=)
AU (1) AU2021250303A1 (https=)
BR (1) BR112022018996A2 (https=)
CA (1) CA3176265A1 (https=)
CO (1) CO2022014886A2 (https=)
CR (1) CR20220554A (https=)
DO (1) DOP2022000203A (https=)
EC (1) ECSP22080683A (https=)
IL (1) IL296823A (https=)
JO (1) JOP20220235A1 (https=)
MX (1) MX2022012067A (https=)
PE (1) PE20221918A1 (https=)
PH (1) PH12022552553A1 (https=)
TW (1) TW202204343A (https=)
WO (1) WO2021198149A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206413A (zh) 2020-04-22 2022-02-16 美商紐羅克里生物科學有限公司 Gpr52調節劑及其使用方法
US12115157B2 (en) 2021-09-14 2024-10-15 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
CN119143731B (zh) * 2024-09-13 2025-08-26 中国海洋大学 一种吡嗪酰胺类化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102089445A (zh) * 2008-05-13 2011-06-08 阿伯丁大学理事会 G蛋白偶联受体相关物质和方法
CN108174603A (zh) * 2015-04-29 2018-06-15 阿芮纳制药有限公司 作为gpr52调节剂的用于治疗或预防其相关病症的1-杂芳基-二氢吲哚-4-甲酰胺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2055500A (en) * 1998-12-23 2000-07-31 Eli Lilly And Company Aromatic amides
WO2009107391A1 (ja) 2008-02-27 2009-09-03 武田薬品工業株式会社 ６員芳香環含有化合物
JPWO2009157196A1 (ja) 2008-06-25 2011-12-08 武田薬品工業株式会社 アミド化合物
WO2011078360A1 (ja) * 2009-12-24 2011-06-30 武田薬品工業株式会社 アミド化合物
EP2530078A1 (en) * 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
WO2011145735A1 (ja) * 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2012020738A1 (ja) * 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
WO2012076063A1 (en) * 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102089445A (zh) * 2008-05-13 2011-06-08 阿伯丁大学理事会 G蛋白偶联受体相关物质和方法
CN108174603A (zh) * 2015-04-29 2018-06-15 阿芮纳制药有限公司 作为gpr52调节剂的用于治疗或预防其相关病症的1-杂芳基-二氢吲哚-4-甲酰胺

Also Published As

Publication number Publication date
CA3176265A1 (en) 2021-10-07
EP4126850B1 (en) 2024-04-17
CN115697997A (zh) 2023-02-03
PH12022552553A1 (en) 2024-01-03
MX2022012067A (es) 2022-10-13
DOP2022000203A (es) 2022-11-30
IL296823A (en) 2022-11-01
US20220356172A1 (en) 2022-11-10
JP7617134B2 (ja) 2025-01-17
CR20220554A (es) 2023-01-09
KR20220161454A (ko) 2022-12-06
WO2021198149A1 (en) 2021-10-07
JOP20220235A1 (ar) 2022-09-28
US11780827B2 (en) 2023-10-10
EP4126850A1 (en) 2023-02-08
AU2021250303A1 (en) 2022-09-22
BR112022018996A2 (pt) 2022-11-01
CO2022014886A2 (es) 2022-10-31
ECSP22080683A (es) 2022-11-30
AR121675A1 (es) 2022-06-29
TW202204343A (zh) 2022-02-01
PE20221918A1 (es) 2022-12-29
JP2023522307A (ja) 2023-05-30

Similar Documents

Publication Publication Date Title
CN115697997B (zh) 具有gpr52促效活性的经取代的3-苯氧基氮杂环丁烷-1-基-吡嗪
TW200950779A (en) Novel glucagon receptor antagonists, compositions, and methods for their use
TW200948364A (en) Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
WO2004110986A1 (ja) ベンズアミド誘導体又はその塩
CN101541782A (zh) 作为凝血酶受体拮抗剂的二环和三环衍生物
US12319701B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
WO2012016569A1 (en) Deuterated tandospirone derivatives as 5-ht1a receptor agonists
US20200024285A1 (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
CN117940420A (zh) 3-苯氧基氮杂环丁烷-1-基-杂芳基吡咯烷衍生物及其作为药物的用途
US8372980B2 (en) Fused ring thrombin receptor antagonists
CA2927527C (en) Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof as u-opioid receptor antagonist
KR102838413B1 (ko) 트리아자사이클로도데칸설폰아미드 (＂tcd＂)계 단백질 분비 저해제
WO2025027049A1 (en) (2s,5r)-5-(hydroxymethyl)morpholine-2-carboxamides as agonists of sstr4
HK40010218A (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
HK1233257B (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
HK1233257A1 (en) Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
WO2006115134A1 (ja) 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant